Ernexa Therapeutics Inc.ERNANASDAQ
Loading
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | -8.89% |
| Q2 2025 | -13.22% |
| Q1 2025 | 13.04% |
| Q4 2024 | 15.68% |
| Q3 2024 | 1.42% |
| Q2 2024 | -32.30% |
| Q1 2024 | 20.50% |
| Q4 2023 | -16.95% |
| Q3 2023 | -2.80% |
| Q2 2023 | -10.45% |
| Q1 2023 | -14.68% |
| Q4 2022 | -60.47% |
| Q3 2022 | 194.54% |
| Q2 2022 | -5.44% |
| Q1 2022 | -58.06% |
| Q4 2021 | 184.98% |
| Q3 2021 | -72.55% |
| Q2 2021 | 254.34% |
| Q1 2021 | -7.17% |
| Q4 2020 | 78.81% |
| Q3 2020 | -6.25% |
| Q2 2020 | 2627.73% |
| Q1 2020 | 0.00% |